Priyanka Verma, PhDWashington University, St. Louis2022 MCM Pilot Study Award Targeting drug resistance in BRCA-mutant ovarian cancers by exploiting endogenous base damage Many ovarian cancers are caused by mutations in proteins that usually function to repair DNA damage. These cancer cells with accumulated DNA damage are targeted by PARP inhibitor therapies. Despite ovarian tumors showing […]
Read More
Toni Antalis, PhDUniversity of Maryland, Baltimore2022 Rosser Family Pilot Study Award Emerging roles of MASP activation in ovarian cancer metastasis and acquired chemoresistance While ovarian cancer responds well to initial treatments, it frequently returns due to acquired chemotherapy resistance. Although chemotherapies aim slow or stop tumor growth, cancer cells continue to evolve between chemotherapy cycles. […]
Read More
Matjaz Barboric, PhDUniversity of Helsinki Examining the Tumor Suppressor Function of Cdk12/CycK Kinase in Ovarian Cancer Failure to understand key mechanisms contributing to the onset of high-grade serous ovarian cancer represents a barrier to diagnosis and treatment of this fifth-leading cause of death among American women. One of the likely factors promoting the disease is […]
Read More
Erinn Rankin, PhDStanford University2016 Pape Family Pilot Study Award Targeting the hypoxic secretome in omental metastasis Mesothelial cells line the abdominal cavity and play an important role in ovarian cancer metastasis. These mesothelial cells in the presence of ovarian cancer tumors are deprived of oxygen (hypoxic) and, as a result, produce components of the hypoxia […]
Read More
Hui Zong, PhDUniversity of VirginiaCharlottesville, VA, United States 2019 Pilot Study Award Research in Focus: Prevention of ovarian cancer Efficacy testing for ovarian cancer prevention at pre-malignant stages with a novel mouse model Prevention remains the ultimate goal for successful management of cancer. Identifying cancer prevention strategies is challenging due to the large population required to […]
Read More